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ABSTRACT: The N,N-dimethylformamide (DMF) as the main solvent with strong dissolving 
power was blended with four secondary solvents (ethanol, n-propanol, isopropanol, propylene 
glycol (PG)) with relatively weak dissolving power to form many new solvents. The dispersion 
index (Inosine (form β) mole fraction) in five organic solvents such as DMF and in the newly 
formed solvent was also obtained one by one with static method commonly used in solid-liquid 
equilibrium. The temperature environment is that the high temperature was set at 323.15 K, and the 
low temperature was set at 278.15 K and the interval between each temperature was 5 K. The 
pressure environment was the atmospheric pressure in the natural state and the usual value was 
101.0 kPa. In a mixed system, temperature was a non-negligible influencing factor from beginning 
to end and its increase often leaded the solute to the trend of high solubility. In addition, the 
proportion of the main solvent also dominated the solubilization trend of the inosine (form β), the 
larger the proportion of DMF, the easier the dissolution process was. When both of the above 
factors were fixed at a certain point, the dispersing ability of the dispersing liquid composed of 
DMF and ethanol was undoubtedly the first. Three models (the Jouyban-Acree model, van’t 
Hoff-Jouyban-Acree model and Modified Apelblat-Jouyban-Acree model) were used to correlate 
the solubility data. The largest RAD and RMSD were 4.66×10-2 and 7.27×10-4. The dispersion data 
of inosine (form β) obtained through this experimental process and related thermodynamic 
parameters obtained through thermodynamic calculations have important application significance 
for its industrial production and further purification. 
■ INTRODUCTION
From the history of the development of chemicals, there are many methods for the purification of 
drugs, such as membrane separation, supercritical fluid technology and so on, but the dissolution 
crystallization technology is undoubtedly the most efficient and cheapest one and the most widely 
used one.1–5 Especially for poorly water-soluble chemicals, how to increase the solubility is a 
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priority problem, because lack of good solubility will affect the development and design of its liquid 
dosage form, bioavailability, and synthesis of downstream products.6–10 There are many ways to 
increase the solute dissolution, such as adding a cosolvent, grinding the solute particles, sonicating, 
adjusting the pH of the solution, adding a surfactant and so on.11–16 Among the various methods 
mentioned above, the method of adding a non-toxic co-solvent to the solvent is currently widely 
used in industry due to its low cost, convenient operation and good results. In addition to the 
above-mentioned advantages, the in-depth study of the dissolution behavior of drugs in a new 
solvent formed by mixing two solvents provides a solid theoretical basis for the interaction between 
solvents and solutes.13,17 
Inosine (C10H12N4O5, CAS No. 58-63-9, molecular weight 268.23 g·mol-1, IUPAC name 
9-((2~(R),3~(R),4~(S),5~(R))-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-3~(H)-purin-6-one, 
molecular structure shown in Figure 1 of supporting information) is known as hypoxanthin or 
hypoxanthine nucleoside that is a nucleoside deriving from a purine derivative antimetabolite, 
containing both a polar furan ring and an apolar aromatic group.18–24 As we know, nucleoside 
derivatives have been extensively investigated due to their potential activity as antibiotics, enzyme 
inhibitors, anticancer, antiviral agents and ATP generation.25–28 It is an important component of 
ribonucleic acids, with the hydrophilic–hydrophobic balance of the molecule contributing to their 
conformational stability which has great impact role on a large number of various chemical and 
biological reactions and other areas.18,19,21
Up to date, two anhydrous polymorphic crystal forms (the orthorhombic α form29 and the 
monoclinic β form18) and a dehydrate30 of inosine have been reported in previous literature. Noting 
that the dihydrate form of inosine is easily crushed to facilitate the extract preparations than other 
polymorphs due to high solubility and dissolution rate in practical usage.18 In view of the fact that 
solid oral preparations may affect the drug solubility due to their different crystalline forms, thereby 
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affecting the bioavailability and clinical efficacy of drugs. On the other hand, the β form shows the 
least soluble ability at room temperature leading to be the most stable thermodynamic product 
among the above. Suzuki31,32 and Tewari et al.19 reported aqua- and aqua-DMSO system solubility 
of inosine (the polymorphism) at different pH values. As well, some aqueous solubility is also seen 
in the ref (33). Hence, there is little studies on the solubility and thermodynamic cosolvency 
conditions of the β form inosine.
According to the survey, inosine is a slightly water soluble drug (0.001059 mole fraction, 
283.15 K) with high permeability.33 Whatever areas the inosine is applied in, the purity of inosine 
must be rather high in demand, in the meanwhile, to achieve the high-purity, stable and uniform 
particle size inosine product, it is necessary to select the best solvent or solvent mixtures to separate 
and purify. The solubility of some drugs strongly depends on the physiochemical properties of the 
drugs and composition of solvent medium.3 In terms of the cosolvency method, non-aqueous 
solvent mixtures are commonly used in drug's crystallization or re-crystallization from synthetic 
reaction solutions.17,34 There are also many requirements on how to choose a suitable solvent in the 
industry. First, the solvent to be selected must be non-toxic. Secondly, it must be chemically stable 
and cannot react chemically with the solute during the dissolution process. 13,17,35,36 It can be firmly 
believed that scientific and accurate dispersion of inosine in various solvents will definitely help it 
in industrial synthesis and will also help its clinical application.
■ THEORETICAL COSOLVENCY MODELS
The models used in this research process are scientifically reliable and have been verified by 
previous researchers.13,17
Jouyban-Acree Model. The Jouyban-Acree model is described as Eq. (1) Quantitatively 
measure the objective effects of temperature and the proportion of main solvent on the dispersion 
of solutes.13,17,37
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where xw,T is solubility of inosine at temperature T; w1 and w2 are proportion of primary solvent and 
secondary solvent; x1,T and x2,T inosine solubility in pure solvents; and Ji are model parameters. 
Van’t Hoff-Jouyban-Acree Model. The Van’t Hoff equation is described as Eq. (2). The 






Combining Eq. (1) and Eq. (2) to achieve the van’t Hoff-Jouyban-Acree model (Eq. (3)).13,17,38
(3)
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A1, B1, A2, B2 and Ji are equation parameters.
Modified Apelblat-Jouyban-Acree Model. The expression of the modified Apelblat equation is 
described as39,40
(4)Tln ln( / )/
Bx A C T K
T K
  
Where A, B, and C are equation parameters; and also xT is solubility of inosine at temperature T.
By substituting Eq. (4) into Eq. (1), the modified Apelblat-Jouyban-Acree model is obtained13,17,39
(5)
2
i1 2 1 2
w,T 1 1 1 2 2 2 i 1 2
0
ln [ ln( / )] [( ln( / )] ( )
/ K / K / K i
B B w wx w A C T K w A C T K J w w
T T T 
       
As usual, the specific value of the dispersion of inosine was calculated using a non-linear 
regression method. The basic basis of the non-linear regression method is the least square method, 
and its functional expression can be described as
        (6) 2e ci i
i=1
ln lnF x x 
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In addition, in order to scientifically compare experimental values with calculated values, the 
relative average deviation (RAD) and root-mean-square deviation (RMSD) are introduced. They are 
























where N is the number of experimental data points.  is solubility determined in this work; and ew,Tx
 is solubility calculated with the corresponding solubility model.cw,Tx
■ EXPERIMENTAL SECTION
Drug, Reagents and Apparatus. Synthesis of Inosine (form β, 0.98 mass fraction) and 
transportation to the laboratory were completed by Meryer (Shanghai) Chemical Technology Co., 
Ltd. The crude drug purchased is dissolved in acetone and a higher purity drug is precipitated by 
cooling the hot saturated solution until its mass fraction reached 0.996 confirmed by a 
high-performance liquid phase chromatograph (HPLC, Shimadzu-6A). The brands of solvents such 
as DMF, ethanol and so on used in the experiment are Aladdin. The minimum purity of the solvent 
used is 0.994 determined by gas chromatography (GC, FULI 9790, China). More detailed 
information of the above chemicals is shown in Table 1.
The tools and instrumentation facilities involved in carrying out this scientific experiment are 
simplified by simple drawing software and shown in Figure 2 of Supporting Information, there is no 
doubt that the instrumentation equipment works and operates in exactly the same way as in previous 
work. 41 In this experiment, first of all, make a glass container (100 mL) with double glass to ensure 
that the interlayer of the container can pass the liquid. The original intention of choosing this design 
was to enable constant temperature operation while using the magnetic stirrer. Of course, the next 
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step is to prepare a suitable circulating liquid, which is usually a mixture of isopropanol and water. 
In order to ensure that the inosine (form β) dissolution process is performed in a constant 
temperature environment, the coordination of the circulating fluid and thermostatic bath 
(QYHX-1030, standard uncertainty: 0.05 K, Shanghai Joyn Electronic Co., Ltd., China) is the key. 
The detection of the system temperature is the key to the success of the experiment. There will 
inevitably be errors in the equipment during the production adjustment process. The introduction of 
a mercury glass micro thermometer (standard uncertainty: 0.02 K) can effectively eliminate the 
errors caused by the instrument measurement. Glass containers are generally open and organic 
solvents are volatile, choosing a suitable latex plug to seal the container can effectively avoid 
solvent loss. An analytical balance (model: BSA224S, standard uncertainty: 0.0001 g, Satorius 
Scientific Instrument (Beijing)) was used to determine the mass of the solute, solvent, and saturated 
solution.
Preparation of Cosolvency Mixture Systems. The use of gravimetric method throughout the 
preparation of new mixed solvents by an analytical balance. The amount of solvent added to the 
glass container is also required. It is generally considered that the amount of solvent added to 
account for half of the entire volume is most suitable, which is 50 g (standard uncertainty: 0.0001 
g). The proportion of the main solvent DMF is added from 0 to 1 and the proportion of each 
increase is 0.1.
Solubility Measurement. The static method runs through the whole process of the inosine 
(form β) data measurement experiment,42-47 and When the solute and the solvent reach a stable state 
with each other, HPLC is the preferred method of characterization. The double-layer glass 
container mentioned above is the main vessel that dissolves Inosine (form β) until it reaches 
saturation. How to saturate the solute is also a non-negligible operation step. There must be a 
surplus of solute added before the solute system can be considered to be saturated. While adding 
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the solute, the full stirring process needs to be completed with the help of a magnetic stirrer. After 
one hour, 1 mL of the inosine solution was extracted by a heat-treated syringe (2 mL) with a pore 
syringe filter (PTFE 0.2 μm) in advance, the sample was diluted and other steps were processed, 
and then it was sent to HPLC for mapping. Repeat the above operation until there are almost no 
differences in the results obtained three times in a row. It can be considered that the dissolution has 
reached a dynamic equilibrium. Scientific operations are the basis for obtaining accurate data. In 
addition, two experimental operations are performed simultaneously to obtain a scientific and 
reliable saturated solution. A method called forward operation is to gradually add a solute to a 
solvent until a solid solute remains. The other method is called the reverse method, which is to 
gradually evaporate the solvent by heating until the solid crystals precipitate. Finally, two sets of 
control samples were placed in the same environment for one hour at the same time. According to 
the above sampling operation, transfer the sample to a 25mL volumetric flask, dilute to a constant 
volume and shake it for instrument analysis. 
The solubility of inosine (form β) ( ) is calculated with Eq. (9), and mass percent of primary w,Tx
and secondary solvents is calculated with Eqs. (10) and (11).
      (9)1 1w,T
1 1 2 2 3 3
m Mx
m M m M m M

 












Here, m1 is the mass of inosine (form β), m2 is mass of DMF, and m3 is the mass of secondary 
solvents. M1, M2 and M3 molar mass of them.
Analysis Method. The Agilent-1260 HPLC is equipped with a reverse phase column (Model: 
LΒ-C18 (250 mm × 4.6 mm)) and its usual operating temperature was set at 303 K. Before setting 
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the ultraviolet absorption wavelength of inosine, a UV scanning operation is required. The result 
obtained is that the maximum absorption wavelength of UV-vis detector is set to 248 nm. The 
mobile phase was pure methanol with a flow rate of 0.8 ml·min−1. Prepare three samples for each 
sample before injecting them and then analyze these samples to obtain three data. If the three data 
are not significantly different, take their average as the final result (relative standard uncertainty: 
0.015). 
X-ray Powder Diffraction. Exploring the crystal structure of solid medicine inosine (form β), 
the X-ray Powder Diffraction (XPRD, Bruker AXS D8 Advance) is a more direct and efficient 
choice. It is equipped with Cu Ka radiation (λ=1.54184 nm) and the tube voltage is 40 kV and 
current is 30 mA. Set the diffraction angle (2-Theta) with 5° as the starting point and 80° as the end 
point at a scan speed of 5°·min-1 under room temperature and 101.0 kPa.
■ RESULTS AND DISCUSSION
XPRD Results. The inosine (form β) sample without any treatment and the sample spectrum 
after dissolving out are plotted in Figure 3 of supporting information. Vertically, the positions of 
characteristic peaks are basically at the same diffraction angle, and the size and shape of the 
characteristic peaks are basically similar. It can be explained that the crystal form of the drug that 
has undergone dissolution is basically the same as that of the untreated raw material sample, and 
there is no change.
Equilibrium Solubility. The mole fraction of inosine (form β) obtained in experiments in 
various mixed solvents with different proportions of DMF are listed in Tables 2, 3, 4 and 5. The 
relationship between the measured solubility and temperature and solvent composition are 
demonstrated graphically in Figures 1-4. That can be also seen from Tables 2-5 that decrease and 
increase in temperature are decisive for the direction of the dissolution process. Not to mention, as 
the proportion of DMF changes, the solubility of solvents to solutes varies widely. 
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The Mathcad software as a commonly used mathematical calculation software is also used for 
the calculation of this data. First enter the corresponding formula (Eqs. (1) to (5)) into it, and then 
enter the experimental value to get the calculated value and related model parameters with RAD and 
RMSD, which are listed in Table 6. 
■ CONCLUSION
The equilibrium solubility of inosine (form β) was obtained one by one with static method 
commonly used in solid-liquid equilibrium. The N,N-dimethylformamide (DMF) as the main 
solvent with strong dissolving power was blended with four secondary solvents (ethanol, 
n-propanol, isopropanol, propylene glycol (PG)) with relatively weak dissolving power to form 
many new solvents. The temperature environment is that the high temperature was set at 323.15 K, 
and the low temperature was set at 278.15 K and the interval between each temperature was 5 K. 
The pressure environment was the atmospheric pressure in the natural state and the usual value was 
101.0 kPa. A solvent combination of DMF and ethanol has unparalleled advantages in dissolving 
inosine (form β). The inosine (form β) solubility was calculated a with three models, the largest 
RAD and RMSD were 4.66×10-2 and 7.27×10-4. The dispersion data of inosine (form β) obtained 
through this experimental process and related thermodynamic parameters obtained through 




Supporting Information Available: Chemical structure of inosine (Figure S1), experimental 
apparatus (Figure S2), XRD patterns (Figure S3).
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Figure 1. Mole fraction solubility (x) of inosine in DMF (w) + ethanol (1-w) solutions with various mass fractions 
at different temperatures: w, mass fraction of DMF; ☆, w=1; ▲, w=0.9009; ○, w=0.7985; ■, w=0.6998; ★, 
w=0.6012;◆, w=0.4993; ◇, w=0.3997; ▼, w=0.3013; △, w=0.2001; ●, w=0.1007; □, w=0; —, calculated curves 
by the Jouyban−Acree model.
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Figure 2. Mole fraction solubility (x) of inosine in DMF (w) + n-propanol (1-w) solutions with various mass 
fractions at different temperatures: w, mass fraction of DMF; ☆, w=1; ▲, w=0.9005; ○, w=0.8015; ■, w=0.7021; ★, 
w=0.6003; ◆, w=0.5000; ◇, w=0.3986; ▼, w=0.2978; △, w=0.2003; ●, w=0.0997; □, w=0; —, calculated curves 
by the Jouyban−Acree model.
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Figure 3. Mole fraction solubility (x) of inosine in DMF (w) + isopropanol (1-w) solutions with various mass 
fractions at different temperatures: w, mass fraction of DMF; ☆, w=1; ▲, w=0.9011; ○, w=0.7996; ■, w=0.7002; 
★, w=0.5993; ◆ , w=0.5001; ◇ , w=0.4011; ▼, w=0.3009; △, w=0.2005; ●, w=0.0997; □, w=0; —, calculated 
curves by the Jouyban−Acree model.
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Figure 4. Mole fraction solubility (x) of inosine in DMF (w) + PG (1-w) solutions with various mass fractions at 
different temperatures: w, mass fraction of DMF; ☆, w=1; ▲, w=0.9012; ○, w=0.8000; ■, w=0.7001; ★, 
w=0.5986; ◆ , w=0.5003; ◇ , w=0.4015; ▼, w=0.2998; △, w=0.2003; ●, w=0.1000; □, w=0; —, calculated 
curves by the Jouyban−Acree model
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Ethanol 64-17-5 46.07 0.998 None GCb
n-Propanol 71-23-8 60.10 0.996 None GC
Isopropanol 67-63-0 60.10 0.996 None GC






68-12-2 73.10 0.994 None GC
a High-performance liquid chromatography.
b Gas chromatography.
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Table 2. Experimental solubility ( ) of inosine in DMF (w) + ethanol (1-w) mixture with T = (278.15 to 3×10eT,wx
323.15) K at p = 101.0 kPa.a
w
T/K
0 0.1007 0.2001 0.3013 0.3997 0.4993 0.6012 0.6998 0.7985 0.9009 1
278.15 0.03160 0.3086 1.007 1.727 2.112 2.359 2.777 3.597 4.575 5.550 6.309 
283.15 0.04282 0.4034 1.294 2.209 2.703 3.025 3.566 4.617 5.700 7.000 8.121 
288.15 0.05672 0.5191 1.648 2.816 3.468 3.912 4.646 6.048 7.375 9.000 10.85 
293.15 0.07401 0.6594 2.075 3.551 4.405 5.013 6.001 7.861 9.650 11.925 14.43 
298.15 0.09594 0.8296 2.578 4.402 5.477 6.261 7.525 9.877 12.29 15.21 18.31 
303.15 0.1237 1.039 3.188 5.429 6.771 7.772 9.371 12.32 15.86 19.28 23.04 
308.15 0.1602 1.306 3.952 6.703 8.367 9.625 11.62 15.28 19.80 24.19 28.67 
313.15 0.2000 1.586 4.748 8.036 10.058 11.62 14.08 18.54 25.03 29.90 35.10 
318.15 0.2527 1.949 5.761 9.716 12.17 14.09 17.11 22.54 31.33 36.69 42.83 
323.15 0.3150 2.368 6.923 11.65 14.63 17.00 20.70 27.32 39.08 45.41 52.32 
a Standard uncertainties u are u(T) = 0.02 K, u(p) = 0.15 KPa; Relative standard uncertainty ur is ur (x) = 0.015. ur(w) 
= 0.0002. w represents the mass fraction of DMF.
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Table 3. Experimental solubility ( ) of inosine in DMF (w) + n-propanol (1-w) mixture with T = (278.15 3×10eT,wx
to 323.15) K at p = 101.0 kPa.a
w
T/K
0 0.0997 0.2003 0.2978 0.3986 0.5000 0.6003 0.7021 0.8015 0.9005 1
278.15 0.02079 0.1839 0.6228 1.125 1.496 1.772 2.146 2.843 4.005 4.988 6.309 
283.15 0.02697 0.2317 0.7752 1.398 1.867 2.227 2.713 3.609 5.102 6.188 8.121 
288.15 0.03835 0.3186 1.048 1.877 2.504 2.988 3.641 4.838 6.824 8.141 10.85 
293.15 0.05388 0.4335 1.403 2.498 3.330 3.978 4.851 6.442 9.070 10.224 14.43 
298.15 0.07126 0.5565 1.775 3.147 4.196 5.025 6.140 8.159 11.48 12.93 18.31 
303.15 0.09500 0.7195 2.259 3.980 5.301 6.350 7.759 10.30 14.46 16.14 23.04 
308.15 0.1233 0.9080 2.812 4.931 6.567 7.882 9.645 12.80 17.96 20.51 28.67 
313.15 0.1595 1.141 3.482 6.071 8.075 9.696 11.86 15.73 22.02 25.86 35.10 
318.15 0.2045 1.424 4.284 7.429 9.872 11.86 14.52 19.23 26.87 33.05 42.83 
323.15 0.2607 1.768 5.252 9.066 12.04 14.49 17.75 23.50 32.80 41.59 52.32 
a Standard uncertainties u are u(T) = 0.02 K, u(p) = 0.15 KPa; Relative standard uncertainty ur is ur (x) = 0.015. ur(w) 
= 0.0002. w represents the mass fraction of DMF .
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Table 4. Experimental solubility ( ) of inosine in DMF (w) + isopropanol (1-w) mixture T = (278.15 to 3×10eT,wx
323.15) K at p = 101.0 kPa.a
w
T/K
0 0.0997 0.2005 0.3009 0.4011 0.5001 0.5993 0.7002 0.7996 0.9011 1
278.15 0.005500 0.07522 0.3459 0.7790 1.130 1.380 1.675 2.214 3.195 4.605 6.309 
283.15 0.008500 0.1104 0.4911 1.084 1.553 1.879 2.260 2.954 4.212 5.996 8.121 
288.15 0.012550 0.1562 0.6784 1.517 2.029 2.742 3.326 3.994 5.670 8.038 10.85 
293.15 0.018400 0.2197 0.9325 2.061 2.742 3.691 4.513 5.374 7.361 9.283 14.43 
298.15 0.026150 0.2995 1.241 2.705 3.454 4.640 5.699 6.936 9.515 12.04 18.31 
303.15 0.03655 0.4022 1.628 3.505 4.695 5.882 7.197 8.861 11.91 15.27 23.04 
308.15 0.05135 0.5426 2.143 4.550 5.718 6.904 8.712 11.25 14.66 20.12 28.67 
313.15 0.07310 0.7402 2.846 5.510 6.667 8.091 10.37 14.20 18.08 24.27 35.10 
318.15 0.1012 0.9852 3.698 7.007 8.091 9.515 12.75 17.73 22.02 32.89 42.83 
323.15 0.1387 1.301 4.773 8.089 9.735 11.63 15.87 22.09 26.82 40.43 52.32 
a Standard uncertainties u are u(T) = 0.02 K, u(p) = 0.15 KPa; Relative standard uncertainty ur is ur (x) = 0.015. ur(w) 
= 0.0002. w represents the mass fraction of DMF.
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Table 5. Experimental solubility ( ) of inosine in DMF (w) + PG (1-w) mixture with T = (278.15 to 323.15) 3×10eT,wx
K at p = 101.0 kPa.a
w
T/K
0 0.1000 0.2003 0.2998 0.4015 0.5003 0.5986 0.7001 0.8000 0.9012 1
278.15 0.001787 0.04573 0.2809 0.6810 0.9988 1.188 1.422 1.925 2.979 4.403 6.309 
283.15 0.002532 0.06149 0.3676 0.881 1.290 1.537 1.843 2.494 4.056 5.718 8.121 
288.15 0.004043 0.0926 0.5343 1.257 1.821 2.155 2.565 3.441 5.608 7.507 10.85 
293.15 0.006050 0.1315 0.7381 1.714 2.472 2.921 3.473 4.643 7.270 9.169 14.43 
298.15 0.009185 0.1887 1.024 2.333 3.327 3.902 4.603 6.093 9.406 11.54 18.31 
303.15 0.01321 0.2580 1.360 3.054 4.327 5.057 5.945 7.827 11.23 14.79 23.04 
308.15 0.01892 0.3514 1.800 3.981 5.598 6.513 7.622 9.970 13.79 18.77 28.67 
313.15 0.02739 0.4830 2.398 5.212 6.251 7.997 9.727 12.60 17.11 23.52 35.10 
318.15 0.03876 0.6511 3.141 6.719 8.003 9.364 12.29 15.80 21.15 29.69 42.83 
323.15 0.05421 0.8693 4.082 8.008 9.118 11.35 15.47 19.76 25.75 37.85 52.32 
a Standard uncertainties u are u(T) = 0.02 K, u(p) = 0.15 KPa; Relative standard uncertainty ur is ur (x) = 0.015. 
ur(w) = 0.0002. w represents the mass fraction of DMF.
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Table 6. Values of parameters obtained from the selected thermodynamic models.
Jouyban−Acree model Van't Hoff−Jouyban−Acree model Modified Apelblat−Jouyban−Acree model
parameter value parameter value parameter value
J0 1875.84 A1 9.77173 A1 109.026
J1 -2401.51 B1 -4109.96 B1 -8641.56
J2 2314.39 A2 6.07107 C1 -14.7520
B2 -4567.14 A2 18.9671
J0 1868.07 B2 -5157.28
J1 -2412.44 C2 -1.91596




RAD·102 2.53 3.04 2.69
RMSD·104 6.80 7.00 6.85
J0 1786.70 A1 9.77173 A1 109.026
J1 -2343.26 B1 -4109.96 B1 -8641.56
J2 1961.21 A2 7.27348 C1 -14.7520
B2 -5016.46 A2 69.9696
J0 1773.94 B2 -7891.84
J1 -2345.11 C2 -9.31129




RAD·102 2.39 3.41 2.83
RMSD·104 6.44 6.31 6.45
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J0 2193.10 A1 9.77173 A1 109.026
J1 -2937.50 B1 -4109.96 B1 -8641.56
J2 2107.75 A2 11.1605 C1 -14.7520
B2 -6477.45 A2 -52.3493
J0 2192.63 B2 -3546.09
J1 -2961.84 C2 9.42189





RAD·102 4.26 4.66 4.46
RMSD·104 7.27 7.10 7.19
J0 2671.29 A1 9.77173 A1 109.026
J1 -3730.04 B1 -4109.96 B1 -8641.56
J2 2794.31 A2 11.5909 C1 -14.7520
B2 -6919.78 A2 -1.11098
J0 2666.15 B2 -6332.47
J1 -3745.87 C2 1.88379




RAD·102 3.26 3.92 3.74
RMSD·104 7.10 6.73 7.06
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